TP53 and ovarian carcinoma: Defining the “aberrant” p53 staining by using the criteria for ovarian carcinoma (complete absence, strong nuclear reactivity in ≥60% of tumor cells, or diffuse cytoplasmic staining) may be more suitable than the traditional overexpression concept; however, our results did not demonstrate the direct association of p53 expression with clinical outcome.